A pioneering gene therapy, known as DB-OTO, has demonstrated significant success in restoring natural acoustic hearing in children suffering from profound congenital deafness caused by mutations in the OTOF gene. The findings, emerging from a first-in-human, open-label study, indicate that this innovative treatment has the potential to revolutionize the management of this specific form of inherited deafness, offering a viable alternative to traditional cochlear implants for many young patients. In a cohort of 12 children, a substantial majority experienced marked improvements in their hearing capabilities, with many achieving the ability to hear soft speech without the need for assistive devices.
The Science Behind OTOF-Related Deafness and the Promise of Gene Therapy
Congenital deafness, a condition affecting approximately 1 in 1,000 newborns globally, can stem from a multitude of genetic factors. Among these, mutations in the OTOF gene represent a significant cause, accounting for a notable percentage of inherited deafness. The OTOF gene encodes for otoferlin, a crucial protein that plays an indispensable role in the intricate process of synaptic transmission within the cochlea. Specifically, otoferlin is vital for the communication between the sensory inner hair cells, which detect sound vibrations, and the auditory nerve, which transmits these signals to the brain for interpretation as sound.
In individuals with biallelic OTOF variants, the deficiency or absence of functional otoferlin protein disrupts this critical communication pathway. This breakdown in signal transmission results in profound deafness from birth. Historically, the primary intervention for such profound hearing loss has been cochlear implantation. These devices bypass the damaged or non-functional auditory pathway by directly stimulating the auditory nerve with electrical signals, effectively translating sound into a form the brain can process. While cochlear implants have been life-changing for many, they involve surgically implanting electronic devices and require extensive rehabilitation.
The anatomical integrity of the inner ear in many children with OTOF-related deafness, despite the functional deficit, has long fueled hope for more direct therapeutic interventions. The concept of gene replacement therapy, which aims to introduce a functional copy of the affected gene into the target cells, emerged as a promising avenue. By restoring the production of otoferlin, gene therapy could potentially re-establish the natural, physiological mechanisms of sound detection and transmission, thereby enabling natural acoustic hearing.
The CHORD Trial: A Landmark Study in Gene Therapy for Deafness
The study, conducted as part of the ongoing CHORD trial, represents a significant leap forward in this pursuit. This multicenter, first-in-human, phase 1/2 clinical trial, which has since been amended to a registrational status due to early positive efficacy signals, is evaluating the safety and effectiveness of DB-OTO gene therapy. DB-OTO is a sophisticated therapeutic agent utilizing a dual adeno-associated virus (AAV) vector system. This dual-vector approach is designed to efficiently deliver the human OTOF complementary DNA (cDNA) to the target cells within the cochlea. Crucially, the delivery is under the control of a promoter that specifically targets hair cells, ensuring the therapeutic gene is expressed in the appropriate cellular environment.
The study design involved administering a single intracochlear infusion of DB-OTO. This means the gene therapy was delivered directly into the cochlea, the spiral-shaped cavity of the inner ear where sound is processed. The treatment could be administered in one or both ears, depending on the study protocol and the specific needs of the participant.
Key Findings and Efficacy Data: A Turning Point in Hearing Restoration
The CHORD trial enrolled 12 children aged between 10 months and 16 years, all diagnosed with profound congenital deafness due to biallelic OTOF variants. Profound deafness was rigorously defined by an average audiometric threshold exceeding 90 decibels (dB) of hearing level (HL), a level at which even loud sounds are not perceived without significant amplification.
Of the 12 participants, nine received DB-OTO in a single ear (unilateral treatment), while the remaining three received the therapy in both ears during the same treatment session (bilateral treatment). The primary efficacy endpoint of the study was set at achieving a behavioral pure-tone audiometry average threshold of less than 70 dB HL by week 24 post-treatment. This threshold was carefully chosen by the researchers as it generally signifies a level of hearing that can avoid the necessity of cochlear implantation and enables natural acoustic hearing.
The results at the 24-week mark were overwhelmingly positive. Nine out of the 12 participants (75%) successfully met the primary efficacy endpoint, achieving an average audiometric threshold below 70 dB HL. This statistically significant outcome (P=1.1×10⁻¹³) underscores the remarkable impact of the DB-OTO therapy.
Further reinforcing the efficacy of the treatment, the study also met its key secondary endpoint. This involved assessing auditory brainstem response (ABR) to a click stimulus, with the goal of achieving a normalized hearing level of less than 90 dB. Again, a substantial proportion of participants met this critical measure of auditory nerve function.
When examining the outcomes based on the treatment approach, the difference between treated and untreated ears was stark. Among the nine participants who received unilateral treatment, six of their treated ears achieved the primary endpoint, compared to none of their untreated ears. This direct comparison highlights the localized and targeted effect of the DB-OTO gene therapy. For the three participants who underwent bilateral treatment, all of them met the primary endpoint, with their hearing improvement assessed based on the better-performing ear.
Beyond these objective audiometric measures, the clinical implications were profound. Six participants were able to perceive soft speech without the aid of assistive devices, a significant milestone that can dramatically impact communication, learning, and social interaction. Even more remarkably, three participants achieved average normal hearing sensitivity, a level of auditory function that was previously unimaginable for them.
Follow-up data for eight participants extended beyond the 24-week mark, indicating that the observed hearing improvements were generally stable or continued to improve over time. This sustained efficacy is a crucial factor in the long-term outlook for patients receiving gene therapy.
Safety Profile and Adverse Events
As with any first-in-human study, a thorough assessment of safety is paramount. A total of 67 adverse events were reported or noted to have worsened during or after the treatment period. Of these, 17 were considered to be related to the surgical delivery procedure itself, highlighting the importance of meticulous surgical technique.
Two serious adverse events (SAEs) were documented. One involved mastoiditis, an infection of the mastoid bone, which occurred in the contralateral ear of a participant who had received treatment. The other SAE was walking instability. Fortunately, both of these serious events resolved without any lasting negative consequences for the affected children. It is also noteworthy that no adverse event necessitated the discontinuation of the study for any participant. Furthermore, the study found no persistent vestibular safety signals, indicating that the therapy did not lead to ongoing balance issues.
Limitations and Future Directions
While the results of the CHORD trial are highly encouraging, the researchers acknowledge certain limitations inherent in a study of this nature. The small sample size of 12 participants, the single-group design (meaning there was no control group receiving a placebo or standard treatment for direct comparison within the same study period), and the relatively limited follow-up duration are all factors that warrant consideration. Additionally, the partial post hoc evolution of the trial design, a common practice in early-phase gene therapy studies as understanding of the therapy’s effects grows, also adds a layer of complexity to the interpretation of the data.
Despite these limitations, the compelling efficacy signals have propelled the trial to a registrational status, indicating that regulatory bodies will be closely scrutinizing these results for potential approval. Future research will likely focus on larger, randomized controlled trials to further validate these findings, extend the follow-up period to assess long-term durability and safety, and explore the optimal dosing and delivery strategies for DB-OTO.
Broader Impact and Implications
The success of DB-OTO gene therapy for OTOF-related deafness carries profound implications for the field of genetic medicine and for individuals affected by inherited hearing loss. It represents a significant validation of the gene therapy approach for conditions previously considered intractable without prosthetic devices. This breakthrough could pave the way for similar gene-based therapies targeting other genetic causes of deafness, potentially expanding the number of children who can benefit from such interventions.
The ability to restore natural acoustic hearing, rather than merely bypassing the auditory system, offers a more holistic and potentially richer auditory experience. This could lead to improved speech development, enhanced language acquisition, better academic performance, and greater social integration for affected children.
The economic and societal impact is also substantial. While the initial cost of gene therapy can be high, the potential long-term savings associated with reduced reliance on lifelong assistive devices and specialized educational support could be significant. More importantly, it offers the prospect of a life with unhindered auditory perception, a gift that is invaluable.
The swift progress of the CHORD trial, from initial phase 1/2 investigation to amendment for registrational status based on early efficacy signals, reflects the urgent need and immense potential for effective treatments for genetic deafness. This development marks a pivotal moment, shifting the paradigm of care from management to restoration for a significant subset of children born with profound hearing loss. The journey from laboratory discovery to clinical application has been arduous, but the results of the DB-OTO therapy offer a beacon of hope for a future where inherited deafness is no longer an insurmountable barrier to experiencing the world of sound.
Citation: Valayannopoulos V, et al. DB-OTO gene therapy for inherited deafness. N Engl J Med. 2026;394:1074-1083. doi:10.1056/NEJMoa2400521
